InterventionsReview

Obesity and Cardio-Metabolic Health in Kidney Disease: Implications for Kidney Health, Risk Stratification, and Management

Clinical Journal of the American Society of Nephrology

The paper

Roy O. Mathew, A. Hong, Yoko Narasaki,

Enrica Fung, Dianne S Cheung, Jennifer Han, Matthew S. Durstenfeld, Priscilla Y. Hsue,

Loma Linda University · University of California, Los Angeles

Clinical Journal of the American Society of Nephrology · 11 Sep 2026

doi.org/10.2215/cjn.0000001233 PubMed 42726513

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
Cardiovascular risk from metabolic burden weakens with age
The Lancet Regional Health Western Pacific · 4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026